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Background: Valuable clone collections encoding the complete ORFeomes for some model organisms have been
constructed following the completion of their genome sequencing projects. These libraries are based on Gateway
cloning technology, which facilitates the study of protein function by simplifying the subcloning of open reading
frames (ORF) into any suitable destination vector. The expression of proteins of interest as fusions with functional
modules is a frequent approach in their initial functional characterization. A limited number of Gateway destination
expression vectors allow the construction of fusion proteins from ORFeome-derived sequences, but they are restricted
to the possibilities offered by their inbuilt functional modules and their pre-defined model organism-specificity. Thus,
the availability of cloning systems that overcome these limitations would be highly advantageous.
Results: We present a versatile cloning toolkit for constructing fully-customizable three-part fusion proteins based on
the MultiSite Gateway cloning system. The fusion protein components are encoded in the three plasmids integral to
the kit. These can recombine with any purposely-engineered destination vector that uses a heterologous promoter
external to the Gateway cassette, leading to the in-frame cloning of an ORF of interest flanked by two functional
modules. In contrast to previous systems, a third part becomes available for peptide-encoding as it no longer needs to
contain a promoter, resulting in an increased number of possible fusion combinations. We have constructed the kit’s
component plasmids and demonstrate its functionality by providing proof-of-principle data on the expression of
prototype fluorescent fusions in transiently-transfected cells.
Conclusions: We have developed a toolkit for creating fusion proteins with customized N- and C-term modules from
Gateway entry clones encoding ORFs of interest. Importantly, our method allows entry clones obtained from ORFeome
collections to be used without prior modifications. Using this technology, any existing Gateway destination expression
vector with its model-specific properties could be easily adapted for expressing fusion proteins.
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The availability of genomic data from an ever increasing
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reproduction in any medium, provided the orcould be exploited to solve both existing and future
biotechnology challenges. The huge amount of sequence
data currently being generated calls not only for bioinfor-
matic prediction of open-reading frames (ORFs) and their
putative functions [1], but also for novel screening
techniques (functional metagenomics) that will help
identifying gene products with potential technological
interest [2]. Metagenomics is already revealing a wealth of
new protein families with unknown functions, as well as
distant relatives of other proteins with well-characterised
functions, which will be very valuable for evolutionary and
structural studies [3]. These studies will likely require the
expression of newly-described ORFs in heterologous hosts. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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protein fusions with standard tags might be advantageous.
One of the main hurdles in metagenomic screening
derives from the existence of profound differences in
the way that different taxonomic groups of organisms
translate ORFs (i.e. codon bias and use of different
initiation codons) [2]. These differential features demand
for the creation of flexible cloning and expression
systems allowing protein expression in multiple hosts
[4]. Furthermore, the prediction of the whole ORF
complement of an organism (the so called ORFeome)
based on the analysis of genomic data has facilitated
the creation of representative clone collections that
contain a large proportion of such ORFs [5]. The
functional characterization of putative ortholog genes
identified among ORFeome clone collections might
involve monitoring their intracellular behaviour, a task
facilitated by the generation of fusions with genetically-
encoded fluorescent proteins [6]. Controlling for possible
artefacts caused by steric interference of the fluorescent
module with important functional domains in the protein
of interest should ideally involve comparing the intracellu-
lar behaviour when the fluorescent module is attached to
either the N- or the C-termini, as well as with that of the
protein over-expressed on its own [7], as it may explain
unexpected behaviours. It might also be necessary to
exchange the fluorescent module so to find the one
with the spectral properties best suited to a particular
experiment [7]. Meeting those demands may lead to
time-consuming subcloning strategies, which would
be further complicated by the intrinsically limited
availability of in frame-, pre-inserted functional modules
in expression vector backbones. The simplification of
subcloning strategies, at least allowing the simultaneous
insertion of the ORFs of interest into a panel of different
expression vectors, would be advantageous [5]. One cru-
cial step in this direction has been the implementation of
recombination-based cloning systems such as the Gateway
kits commercialized by Invitrogen (Life Technologies).
Gateway cloning, which has been adopted for the creation
of many ORFeome clone collections [5], bypasses the
constraints imposed by restriction and ligation strategies
and, in its basic configuration, is based on the recombinase-
mediated shuttling of a DNA fragment (e.g. an ORF) from
an entry clone into a destination vector. DNA fragments
are transferred between vectors regardless of their sequence
thanks to flanking recognition signals (the att sites) targeted
by recombinases that have been borrowed from the λ
phage’s lysogeny cycle machinery [8]. The creation of
an entry clone typically (but not exclusively) involves
the PCR-mediated attachment of flanking attB sites to the
DNA of interest, and its recombination-mediated
cloning into an attP-containing plasmid. Recombination
of this entry clone with an appropriate destination vectorcontaining compatible att sequences will lead to an
expression vector encoding an ORF, provided that the
destination vector is furnished with a suitable promoter.
The expression of an ORF of interest as a fusion with a
fluorescent protein can be achieved with the help of a
limited number of commercially-available destination
vectors that contain an in-frame pre-inserted module.
Our aim was to develop a system that could meet the
above requirements while avoiding complex subcloning
strategies. Owing to the advantages of Gateway cloning, we
generated a customizable Gateway-based plasmid toolkit
for constructing fusion proteins from any ORF available as
a standard entry clone. ORFs can be optionally expressed
on their own or as in-frame fusions with a collection of
standardized functional modules, in a combinatorial way,
and from any Gateway destination expression vector. We
describe the design and components of the toolkit,
and we demonstrate its feasibility by presenting
proof-of-principle expression data obtained in transient
transfection experiments with prototype vectors encoding
fluorescent fusion proteins.
Results and discussion
Conceptual design of the cloning toolkit
The construction of a vector for the expression of fusion
proteins requires the subcloning of the cDNA of interest
into a vector’s backbone, at a site next to one or more
pre-existing in-frame modules that provide the functions
to be monitored. Hence, the design of the preassembled
backbone vector conditions the nature of the fusion and
the relative position of its constituent modules. This
limits the possibilities for screening the best modular
arrangement and performance. Subcloning of fusion
proteins could be streamlined by releasing the functional
modules from a fixed position in the backbone vector
and regarding them as exchangeable modules to be
cloned at the N- and C-termini simultaneously with the
ORF of interest (Figure 1A). Ideally, such an approach
would be based on recombination-mediated cloning
since this should allow standardisation of the procedures
and of the peptides linking the modules, facilitating the
adoption of high-throughput technology, as described in
earlier reports [9,10]. Expressing a protein optionally on
its own or as a fusion with two flanking modules
from a single vector backbone would be an additional
asset (Figure 1A). Thus, when expressed under uniform
conditions, comparing a protein’s behaviour in either
circumstance would facilitate the identification of poten-
tial artefacts occurring as a consequence of the fusion with
functional modules [6]. It would also allow a large number
of fusions based on a given ORF to be cloned simultan-
eously into an array of model-specific expression vectors
in combination with a collection of functional modules
(Figure 1B). A cloning toolkit with such features would
AB
ORF of interest
N-term C-term
Figure 1 A combinatorial strategy for the expression of
proteins as fusions with functional modules. A. Our toolkit’s
design allows any ORF of interest to be easily expressed either on its
own (above) or as a fusion (below) with N- and C-terminal modules
picked from among a collection of parts (represented as
multicoloured wheels). The fusion’s components are linked by
standardized short peptide arms (black spheres and triangles)
introduced as a result of the cloning procedure. The collection is
constructed so that a given functional module can be attached
either at the N-terminal or the C-terminal side of the protein of
interest, which is helpful for finding the optimal arrangement in
each case. B. Multiple fusions can potentially be generated by
combining an ORF of interest with different modules from the collection.
Specific fusions aimed at particular applications will be defined by the
choice of modules used. For example, an ORF of interest N-terminally
tagged with different fluorescent modules (green, yellow, blue) can be
used to monitor the fusion protein’s intracellular localization under
conditions best suited for each experiment. Furthermore, our versatile
design allows a particular fusion protein arrangement to be cloned into
vectors specific for expression in different model systems in the context
of comparative studies.
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according to similar design principles [10]. Furthermore,
our toolkit would ideally tap into the wealth of ORFeome
resources produced by the efforts of different laboratories
leading the mass-production of parts for systems biology
[5], a feature shared with previous designs [9,10]. We chose
a cloning toolkit developed with the MultiSite Gateway
three-fragment vector construction kit from Invitrogen
(See Additional file 1) as it would make it meet the require-
ments above. A recombination reaction involving three
separate entry clones based on the pDONR vectors from
the kit (pDONRP4-P1R, pDONR221 and pDONRP2R-P3)
and containing DNA fragments flanked by specific variants
of the att sites, results in their ordered subcloning into
the kit’s promoterless destination vector pDEST-R4-R3(See Additional file 1). Interestingly, the DNA fragment
that occupies the central position is flanked by attL1 and
attL2 sites in its entry vector (pDONR221), just as in the
entry vectors available from public or commercial cDNA
resources (e.g. ORF shuttle clones available through the
ORFeome Collaboration [11,12]). Furthermore, new entry
clones constructed by PCR-amplification of cDNAs and
their BP clonase-mediated recombination into vectors
containing attP1/attP2 sites used for standard Gateway
cloning are also compatible with the MultiSite Gateway kit
(Figure 2, panel 1) (Also see Additional file 1). The preser-
vation of the translation frame of the three fragments
that are pieced together was built into the original
MultiSite cloning system’s design [9]. Therefore, by
cloning the N-term- and C-term-functional modules
proposed in the toolkit’s design into pDONR-P4-P1R
and pDONR-P2R-P3, respectively, they could join an
entry vector holding the ORF for a protein of interest
in a MultiSite cloning reaction that would create a
fusion protein’s chimeric ORF (Figure 2, panel 2).
However, pDEST-R4-R3 is a promoterless destination
vector, meaning that further engineering of this vector
would be required in order to insert a promoter upstream
of the chimeric ORF. Instead, replacing the original
single-fragment Gateway cassette in any destination
expression vector furnished with a heterologous promoter,
with the R4-R3 cassette from pDEST-R4-R3 seemed a
more powerful strategy (Figure 2, panel 3). This would
allow taking advantage of numerous existing Gateway
destination vectors that would become in this way
available for MultiSite Gateway cloning (see also ref. [13]),
increasing the functional flexibility of the toolkit. This way,
the protein of interest could be expressed on its own or as
a fusion protein in the context of the same vector back-
bone, by choosing for the LR-recombination between the
unmodified vector and that with the engineered Gateway
cassette, used in combination with the clones encoding
functional modules. Furthermore, all of the elements in the
proposed collections of flanking N-terminal and C-terminal
functional modules would partake of the same construction
principles. Thus, they could be used in a combinatorial
fashion in MultiSite Gateway LR Clonase-mediated recom-
bination reactions with any existing Gateway entry clone
containing an attL1/attL2-flanked ORF, where the compo-
nents of the fusion proteins would be linked by the trans-
lated remaining attB1 and attB2 sequences acting as
universal connectors (Figure 2, panel 4). The open architec-
ture of such toolkit would allow for easily updating any suc-
cessful fusion arrangement to the latest versions of the
functional modules in use (e.g. fluorescent proteins). This
would be achieved by simply incorporating such ver-
sions as new modules in the collection, so they could be
used instead of the superseded modules in a replay of the
recombination reaction that led to the fusion in question.
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Figure 2 Strategy for the cloning of fusion proteins. Cloning is based on the Multi-site Gateway kit from Invitrogen. The plasmid encoding
the ORF of interest can either be an existing entry clone from a Gateway-based ORFeome library, or can be constructed by Gateway-cloning the
PCR-amplified ORF into pDONR221 with BP clonase (panel 1). A collection of entry clones encoding the functional modules to be attached to
the ORF of interest is constructed similarly by Gateway cloning the PCR-amplified modules into the pDONR P4-P1R (N-term modules) and pDONR
P2RP3 (C-term modules) plasmids from the MultiSite Gateway kit (panel 2, see main text for details). All of the inserts in the entry vectors are
flanked by appropriate att sites provided by the PCR-amplification primers, and are indicated throughout this figure with a key (e.g. the attB1 site
is indicated as B1). Single-fragment Gateway destination expression vectors designed for expression in different model systems are adapted by
engineering of the Gateway cassette to allow MultiSite Gateway cloning reactions (panel 3). Such reactions involve one adapted destination
vector, as well as the plasmids encoding the ORF of interest and the chosen N-term and C-term modules (white background), whose matching
att sites (R4xL4, R1xL1, L2xR2, L3xR3) recombine to produce a destination expression vector encoding the fusion protein in the form of a chimeric
cDNA (panel 4). Expression of the cDNA results in the production of a fusion protein whose three constituent parts are linked by short peptides
resulting from the translation of the attB1 and attB2 sites remaining after the LR recombination (panel 4, see main text for details).
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three-fragment cloning
The substitution of the single site- by the MultiSite
attR4-attR3 Gateway cassette in an existing destination
expression vector was achieved by modifying a method first
reported by Magnani and colleagues [13]. This consists of
an LR-recombination reaction between a vector that con-
tains the attR4-attR3 Gateway cassette from pDEST-R4-R3,
flanked by attL1/attL2 sites (pDONR221-R4-R3), and
the destination expression vector in its standard form,
furnished with attR1/attR2 sites [13]. In this way, a suc-
cessful recombination reaction would place the R4-R3
Gateway cassette between attB1 and attB2 sites (resulting
from the LR recombination between attL1/attL2 andattR1/attR2 sites). However, such a procedure raised a
technical issue, common to all reactions where standard
Gateway cassettes are replaced with versions containing
different flanking recombination sites, i.e. how to easily
distinguish, after bacterial transformation, between E. coli
colonies that contain the original destination vector from
those containing the vector with the recombined R4-R3
Gateway cassette, since they would be identical in terms
of their selection markers. To solve this issue, we took
advantage of the fact that Gateway vectors typically
possess two antibiotic resistance genes, one of them being
the chloramphenicol-acetyl transferase (CAT) gene that
lies inside the Gateway cassette, and another one that
lies elsewhere in the vector. The ccdB-resistant E. coli
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Figure 3 Adaptation of existing Gateway Destination vectors
for the expression of fusion proteins. A. Construction of adapter
vector pDONR221-R4-R3. A PCR product corresponding to the
attR4-attR3-containing Gateway cassette in pDEST-R4-R3 was
amplified with primers that provided flanking attB1 and attB2 sites.
An inactivating mutation was introduced into the CAT gene (red X)
in pDONR221 by site-directed mutagenesis so that ccdB-resistant E.
coli transformed with this plasmid were sensitive to chloramphenicol
(CamS). A BP-recombination reaction was set up between the
amplified attR4-attR3 Gateway cassette and pDONR221_CamS to create
pDONR221-R4-R3 (see details under methods). The att sites involved in
the reaction are marked with blue squares. Selection with LB medium
containing kanamycin and chloramphenicol (Kan/Cam) yielded colonies
containing the recombined plasmid. B. Adaptation of destination
expression vector pEF5/FRT/V5-DEST for MultiSite Gateway
recombination reactions. The same inactivating mutation in the CAT
gene as above (red X) was introduced into the commercially available
single-site destination expression vector pEF5/FRT/V5-DEST to generate a
Cam-sensitive version (pEF5/FRT/DEST-CamS). The mutant plasmid was
subjected to an LR-recombination reaction with pDONR221-R4-R3 in
order to replace its original Gateway cassette with the attR4-attR3
MultiSite recombination cassette in pDONR221-R4-R3 (endowed with a
wild type CAT gene). The att sites involved in the reaction are marked
with green squares. Selection of the colonies containing recombined
pEF5/FRT/V5-DEST (pEF5/FRT/-DEST-R4-R3) was carried out with LB
medium containing ampicillin and chloramphenicol (Amp/Cam). Only
the features in the pEF5/FRT/V5-DEST plasmid map that are relevant for
the reaction are shown.
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to both chloramphenicol and the antibiotic (ampicillin,
kanamycin, etc.) specified by the other resistance gene.
Our strategy consisted in engineering the vector before
the recombination reaction, so that an inactivating
mutation was introduced by site-directed mutagenesis
into the CAT gene in the existing Gateway cassette,
while the rest of the vector’s functionality was preserved. E.
coli cells transformed with this vector were sensitive to the
presence of chloramphenicol in the culture medium
(See Additional file 2). On the other hand, the PCR-
amplified MultiSite Gateway cassette, which was to replace
the original one after recombination, had a functional CAT
gene. Thus, successful recombination would restore the
resistance to chloramphenicol in the engineered vector and
allow the growth of colonies of bacteria in the presence of
chloramphenicol and ampicillin, while negatively selecting
bacteria transformed with the non-recombined destination
vector. Since all Gateway vectors contain the same se-
quence in the CAT gene that is targeted by our mutagenesis
reaction, this strategy could potentially be used for tailoring
the Gateway cassette in any vector. We initially tested it by
assembling the pDONR221-R4-R3 vector (Figure 3A).
This involved a BP-recombination reaction between a
PCR-amplified R4-R3 Gateway cassette furnished with
a wild-type CAT gene, and a CAT-mutant version of
the pDONR221 vector (Figure 3A). The screening strategy
proved to be successful, and we were able to isolate bac-
terial clones containing recombined pDONR221-R4-R3,
as confirmed by sequencing, which were again resistant to
chloramphenicol and kanamycin. We subsequently used
the same strategy in the adaptation of a destination
expression vector for MultiSite Gateway cloning, as
required by the design of our cloning toolkit. Thus,
an LR-recombination reaction was set up between
pDONR221-R4-R3 and the CAT-mutant version of
pEF5/FRT/V5-DEST (Figure 3B). After transformation of
the reaction and plating on LB medium supplemented with
ampicillin and chloramphenicol, several colonies resistant
to both antibiotics were isolated. Sequencing of the plasmid
prepared from these colonies evidenced the presence of an
R4-R3 Gateway cassette flanked by attB1/attB2 sites in the
context of pEF5/FRT/V5-DEST, showing the successful
substitution of the single site- by the MultiSite Gateway
cassette. Thus, we designated this plasmid pEF5/FRT/V5-
DEST-R4-R3 and used it in the construction of the fusion
protein prototypes discussed below. Importantly, the muta-
tion of the destination vectors’ CAT gene required by our
method will not only be useful for enabling MultiSite
recombination cloning, but could also be used subsequently
for other adaptation reactions involving different Gateway
cassettes flanked by other types of recombination sites
(different att sequences, FRT or loxP recombination sites),
which could be screened with the same procedure.Creation of a collection of functional modules
We cloned a collection of functional DNA modules into
vectors pDONR-P4-P1R and pDONR-P2R-P3 so they could
be fused to the N- or C-termini of the protein of interest,
respectively. This was carried out by BP-recombination
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functional modules and either of the pDONR vectors. PCR
products that were to be cloned into pDONR-P4-P1R were
flanked by attB4/attB1 sites, while those to be cloned
into pDONRP2R-P3 were flanked by attB2/attB3 sites
(Figure 2, panel 2). A current list of the components
in our collection of modules is provided as Table 1.
At the moment, they mostly consist of clones containing
the cDNA for a series of fluorescent proteins, which can
be fused either at the N-terminal or C-terminal end of the
ORF of interest. The fluorescent proteins available are
ECFP (cyan), EGFP (green), EYFP (yellow) and mKate2
(far red). There is also a 3′-module that allows expressing
ECFP from an internal ribosome entry site (IRES) in the
context of a bicistronic mRNA shared with a two-module
fusion protein encoded at the 5′-half of the mRNA. We
will introduce modules encoding the A206K EGFP and
EYFP variants, with reduced oligomer formation [14], to
be used in fusions whose behaviour could be affected by
fluorescent protein oligomerization. This will not be
necessary for ECFP-encoding modules since this protein
carries a constitutive mutation that prevents its dimerization
[15]. Since the three entry vectors from the MultiSite
Gateway cloning kit must be present for successful
recombination, we included a non peptide-encoding
3′-module with a stop codon and a SV40 early
polyadenylation signal cassette to allow translational
termination of chimeric ORFs when fusion of a mod-
ule at the C-terminus is not necessary or convenient.
Please note that the parental pEF5/FRT/V5-DEST vector
contains the BGH polyadenylation signal downstream of
the Gateway cassette and this is preserved in pEF5/FRT/
V5-DEST-R4-R3. Thus, when a 3′ peptide-encoding
module is typically used, the BGH polyA signal will
allow proper processing of the chimeric transcript,
with the 3′ module providing the STOP codon at the
end of the encoded peptide. Because an N-terminal tagTable 1 Plasmids encoding functional modules currently
available on the toolkit
5′ module 3′ module
pDONR P4-P1R-mKate2 pDONR P2R-P3-V5-6xHis
pDONR P4-P1R-V5-6xHis pDONR P2R-P3-mKate2
pDONR P4-P1R-EGFP pDONR P2R-P3-IRES_ECFP
pDONR P4-P1R-EYFP pDONR P2R-P3-SV40 polyA signal
pDONR P4-P1R-ECFP pDONR P2R-P3-EGFP
pDONR P2R-P3-EYFP
pDONR P2R-P3-ECFP
Plasmids based on the pDONR P4-P1R vector contain inserts that will be
placed at the 5′ flank of the cDNA and will encode the N-terminal module of
the fusion protein. On the other hand, those based on pDONR P2R-P3 will
transfer their insert to a position flanking the 3′-end of the cDNA, and will add
a C-terminal module to the fusion protein in case they encode a peptide.might interfere with functionally important modifications
of the protein (e.g. myristoylation), we will also obtain a
neutral 5′-module containing an intronic sequence that
can serve a similar function at the N-terminus. We have
also constructed modules containing the well-characterised
V5 and 6xHis epitope tags. Other possible modules would
be those encoding for protein domains that target proteins
to an organelle (e.g. NLS and a mitochondrial targeting
sequence), an application previously demonstrated [9]. The
attB-flanked PCR products were generated in two sequen-
tial PCRs, with two sets of partially overlapping primers
(see Methods section). The sequence of primers used for
creating the current collection of functional modules is pro-
vided as Additional file 3: Table S1. Since all modules in
each category (N- or C-terminal) were cloned the same
way into pDONR-P4-P1R or pDONR-P2R-P3, they were
fully exchangeable and conferred the desired combinatorial
character to the toolkit.
Construction and expression of the fusion protein
prototypes
We constructed a panel of vectors for expressing fusion
proteins in order to test the feasibility of our cloning
toolkit. These vectors were obtained through MultiSite
Gateway recombination reactions between plasmids
encoding the N-terminal modules, the ORFs of interest,
the C-terminal modules, and the pEF5/FRT/V5/DEST-
R4-R3 destination expression vector described above. LR
clonase-mediated recombination between compatible att
sites on the participating plasmids produced a chimeric
ORF that substituted the engineered Gateway cassette on
plasmid pEF5/FRT/V5/DEST-R4-R3. The attB1/attB2 sites
flanking the attR4/attR3 Gateway cassette were not targeted
by the LR-recombinase [13]. Expression of the ORFs
produced fusion proteins where the three component parts
were separated by peptide linker arms resulting from the
translation of the attB1 and attB2 sites flanking the protein
of interest (see above). Since the upstream attB1 and attB4
recombination sites are located between the EF1α promoter
and the translation initiation codon of the N-terminal
module, and the attB3 and downstream attB2 sites lay
beyond the stop codon in the C-terminal module,
none of them would participate in the translated
product (Figure 2, panel 4). Even though there seems
to have been no systematic analysis of the possible
functional interference of the residual attB1/attB2
sites in the expression of fusion proteins [10], individual
studies found those sites to be either neutral [16] or detri-
mental [17] for protein expression, hence the need to assess
their convenience for the intended applications. The fusion
proteins obtained with this approach are listed on Table 2
and are grouped in sets that illustrate some of the possibil-
ities of the cloning toolkit. The first set highlights the com-
binatorial aspect of the collection of functional modules,
Table 2 Panel of expression vectors encoding fusion proteins
Vector 5′-module Central module 3′-module
Set 1
pEF5/FRT-DEST-R4-R3_V5-6xHis: PAR2:mKate2 V5-6xHis PAR-2 mKate2
pEF5/FRT-DEST-R4-R3_V5-6xHis: PAR2: EGFP V5-6xHis PAR-2 EGFP
Set 2
pEF5/FRT-DEST-R4-R3_mKate2: SIRT1 mKate2 SIRT1 SV40 polyA
pEF5/FRT-DEST-R4-R3_mKate2: ΔNtermSIRT1a mKate2 ΔNtermSIRT1 SV40 polyA
Set 3
pEF5/FRT-DEST-R4-R3_mkate2: RelA:V5-6xHis mKate2 p65 V5-6xHis
pEF5/FRT-DEST-R4-R3_V5-6xHis:p65:mKate2 V5-6xHis p65 mKate2
MultiSite Gateway recombination reactions were carried out between the adapted destination expression vector pEF5/FRT-DEST-R4-R3, and plasmids encoding
5′-module, the ORF of interest (central module) and the 3′-module as described. The resulting expression plasmids are listed on the table, with an indication of
the functional modules used for making each fusion protein, and are organised in sets, according to the toolkit properties intended to illustrate (see main text).
The central module encoding wt SIRT1 is an entry clone obtained from an ORFeome library, used in the MultiSite cloning reaction with no prior modifications.
The SV40 polyA module (italics) does not encode for a peptide but contains a polyA signal that precedes the BGH polyA signal provided by the
pEF5/FRT-DEST-R4-R3 vector.
aThe “Δ” symbol stands for “deleted”.
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N-terminal and central (i.e. the protein of interest) modules
but that are fused to different fluorescent proteins at
the C-terminus. This would be helpful for optimising
fluorescent fusion proteins since different combinations can
be produced up front and tested for the existence of steric
hindrance, poor fusion stability and functional interference
by oligomerization of the fluorescent module [18]. Further-
more, it would also provide some flexibility for designing
coexpression experiments, because fusion proteins with
different emission spectra would be available to suit each
case (See panel A, Additional file 4). This set comprises two
fusion proteins containing the Proteinase-activated receptor
PAR2 (V5-6xHis: PAR-2: mKate2 and V5-6xHis: PAR-2:
EGFP, Figure 4A). The second set represents the possibility
of generating mutations in the ORF of interest while still in
the entry clone. In this way, the construction of one muta-
tional library would be sufficient for preparing a range of
expression vector libraries to be screened on different
model systems (mammalian cells, yeast, etc.) or with differ-
ent reporters. This would avoid the need to go through
independent mutagenesis reactions for creating libraries
based on different expression vectors (See panel B,
Additional file 4), and should be helpful for studying
the effects of point mutations or deletions on the function
of the protein of interest (e.g. intracellular trafficking).
This set comprises the wild type (wt) form as well as
an N-terminal deletion of the mouse sirtuin SIRT1
(ΔN-t-SIRT1, Figure 4A), both N-terminally fused to
mKate2. This deletion affects the first nuclear location
signal (N1) and may produce alterations on the intracellu-
lar distribution of the protein [19]. Finally, the third set
represents the two possible arrangements of a fusion pro-
tein with functional modules flanking the ORF of interest
(See panel C, Additional file 4). The ability to generate thetwo proteins up front would facilitate the identification of
the order that causes the least interference on the protein’s
function. Our example consists of two fusion proteins
where the far-red fluorescent protein mKate2 [20]
and a V5-6xHis epitope tag cassette were placed
either N-terminal or C-terminal relative to the human
p65/RelA subunit of NFkB (mKate2: p65: V5-6xHis
and V5-6xHis: p65: mKate2, Figure 4A).
The constructs described above were transiently
transfected into cells in order to test the feasibility of
our approach (Figure 4B, panels a-j). In HeLa cells,
C-terminal fusions of PAR-2 with mKate2 (Figure 4B,
panels a, b) or with EGFP (panels c, d) were expressed
separately in transient transfection experiments. Cells
under control conditions showed localisation of PAR-2
fluorescent fusions mostly at a perinuclear compartment
[21], with a weaker signal located near the plasma mem-
brane (a, c). Treatment of the cells with the PAR-2-specific
agonist AC55541 caused a slight redistribution of the
fluorescent signal from either fusion protein that concen-
trated on a smaller area around the nucleus (b, d). Also in
HeLa cells, expression of wt SIRT1 fused to mKate2
showed nuclear localisation (Figure 4B, panel e), but the
loss of an N-terminal fragment of mSIRT1 encompassing
N1, caused the fusion protein to be localised in the cyto-
plasm (Figure 4B, panel f), in agreement with previous
data [19]. In Raw264.7 monocytes, both the mKate2: p65:
V5-6xHis and V5-6xHis:p65:mKate2 fusions (Figure 4A,
set 3) demonstrated cytoplasmic localisation under con-
trol conditions (Figure 4B, panels g, i), as expected [22].
LPS treatment of the cells induced nuclear translocation
of both fusion proteins (Figure 4B, panels h, j). The exist-
ence of slight differences in the intracellular distribution
of fluorescence between different fusions of the same ORF
(compare panels a and c, or g and i) suggest there might
Figure 4 Expression of fluorescent fusion proteins. A. Schematic representation of the fusion proteins produced in order to test the feasibility
of our toolkit, indicating the micrograph panels in Figure 4B where each protein’s expression is shown. The relative positions of the nuclear
location signals (N1, N2) and nuclear export signals (E1, E2) in murine wild type (wt) SIRT1 is shown. ΔN-tSIRT1, N-terminal-deleted murine SIRT1
(see main text); the portion deleted from the wt isoform is indicated. Fusion proteins are clustered in functional sets, as described in the main
text. B. Detection of fluorescent protein fusions under an epifluorescence microscope. Panels a-d: expression of PAR-2 fused to mKate2 (a,b) or
EGFP (c,d) in transiently-transfected HeLa cells under control conditions (a,c) or after treatment with the PAR2-specific agonist AC55541
(5 μM, 1 h; panels b, d). White bar: 10 μm. Panels e, f: Differential localisation of wt- (e) or ΔN-tSIRT1 (f) proteins fused to mKate2 in transiently-
transfected HeLa cells, under control conditions. White bar: 10 μm. Panels (g-j): expression of two p65/RelA-based fusions with mKate2 after
transient trasfection of their expression vectors into Raw264.7 monocytes, under control (g,i) or LPS-stimulated conditions (100 ng/ml, 1 h; panels
h,j). White Bar: 10 μm. All micrographs were taken at 200X magnification. C. Frames from a time-lapse movie of a Raw264.7 monocyte transfected
with the expression vector for the PAR2-mKate2 fusion protein and imaged on a confocal microscope (63X objective lens) after adding 5 μM
AC55541 in order to monitor cellular trafficking of the receptor. The complete time-lapse experiment is provided as Additional file 5: Movie S1.
Time elapsed after adding the agonist is indicated in each frame. The white arrow in the 20 min-panel points at some PAR2-mKate2-labelled
intracellular vesicles that are seen trafficking in Additional file 5: Movie S1.
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deserve further investigation. If confirmed, they would
illustrate the usefulness of our cloning strategy. As we
pointed out in the background section, the study of theintracellular behaviour of a newly-described protein
may help delineate its possible functions. Our cloning
toolkit would be useful for the generation of fusions
to be specifically used in such studies. This is exemplified
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monomeric fluorescent protein mKate2 to the C-terminus
of PAR-2 was expressed in a Raw264.7 monocyte by
transient transfection of the pEF5/FRT-DEST-R4-
R3_V5-6xHis: PAR2:mKate2 expression vector, and ob-
served under a confocal microscope in a time-lapse experi-
ment aimed at tracking the protein’s behaviour following
treatment with the PAR-2 specific agonist AC55541.
Figure 4C provides a series of still frames extracted from
the time-lapse recording at the indicated times after adding
the agonist. These show the agonist-induced clustering and
internalization of the plasma membrane-associated PAR-2:
mKate2 fusion, as well as the presence of intracellular vesi-
cles containing the fluorescent protein (Figure 4C, arrow),
as previously described [21]. Active perinuclear trafficking
of the vesicles can be appreciated in the complete time-
lapse movie (Additional file 5: Movie S1). Additional file 6
Movie S2 corresponds to a shorter time-lapse sequence of
the same cell recorded under control conditions, just before
adding the agonist, and shows expression of the fusion
protein in continuous association with the plasma
membrane, as well as in some intracellular vesicles that
display a more modest trafficking behaviour.
All the fusion proteins described above were expressed
from pEF5/FRT/V5/DEST-R4-R3, a plasmid derived from
pEF5/FRT/V5/DEST (see above and Methods section).
This is a vector compatible with the FLP-In system
(Life Technologies), which allows the generation of
isogenic clones with stable plasmid integration by
using a selection of cell lines that contain a single
FRT recombination sequence in their genome (FLP-In
cell lines). Thus, our system should facilitate the assembly
of expression vector libraries consisting of fusions between
selected functional modules and a library of randomized
mutations of a cDNA, so they could be stably-transfected
into an FLP-In cell line and screened for a mutation
conferring the properties sought after, in the absence of
clonal variegation caused by genome-positional effects.
Furthermore, this would not be restricted to randomized
mutation libraries, but could also be applied to libraries
consisting of collections of cDNAs (e.g. the Gateway-
based Human Kinase Open Reading Frame Collection
from the Centre for Cancer Systems Biology (DFCI)/
Broad Institute (MIT) [23]). Our system would also be
useful for the generation of chimeric proteins. Thus, a
protein coding sequence could be divided into three
fragments at appropriate sites that did not compromise
the main structure or function of the protein, with
each fragment cloned into one of the three pDONR
vectors in the toolkit. Different isoforms in a family
of proteins could be cloned in this way so that hom-
ologous domains cloned in the same type of pDONR
vector could be shuffled between the isoforms in
order to analyse the impact on the proteins’ function.Similarly, a collection of mutants from a single
domain could be cloned with the remainder of the
wild type ORF in order to screen for residues
involved in a specific function. Although we have not
addressed these specific applications, pioneering work
on the yeast STE2 receptor by Cheo and colleagues
with an analogous set up [9] suggests that our design
could be used in such studies.
Interestingly, some of the clones encoding functional
modules in our toolkit could be exchanged with those
from similar platforms built with the same MultiSite
Gateway cloning kit as ours, expanding the number of
possible fusion protein combinations. One example is
the platform known as Tol2Kit [24]. It consists of a
series of 5′-, middle- and 3′-clones arranged in the
context of several destination vectors specific for
zebra fish transgenesis, and was created to facilitate
the obtention of strains expressing a variety of minigene
constructs consisting of promoter_coding sequence_3′tag
arrangements [24]. Another example is the pTransgenesis
system [25], which consists of collections of entry
vectors initially developed to facilitate the construction of
minigenes to be expressed in transgenic Xenopus strains,
but are also compatible with transgenesis in other model
organisms such as Drosophila, zebrafish and mammalian
cell models, thus facilitating the study of the evolutionarily
conserved properties of biological systems [25]. Finally,
Nagels-Durand and colleagues have recently reported a
novel set of destination vectors specific for expression in
Saccharomyces cerevisae that allow MultiSite recombin-
ation cloning of promoters, ORFs and epitope tags in
combination with a choice of auxotrophy markers and
replication mechanisms in this model organism [26].
Some of the functional modules described in our
work overlap with those from these other platforms
(Table 1 and [24-26]), and have been successfully
used for the applications described therein. Fluores-
cent protein-encoding modules from our toolkit as
well as from the other platforms mentioned above
could also be used as reporters in new projects aimed
at characterizing ORFeome-inspired promoteromes,
such as in the pioneering work of Denis Dupuy and
collaborators [27], who constructed a library of
intergenic regions comprising proximal transcriptional
regulatory elements plus the 5′UTRs cloned in the
pDONR P4-P1R vector, and used it in combination
with ORFs derived from the nematode’s ORFeome in
Multisite Gateway cloning reactions that generated
vectors with a promoter:ORF:reporter arrangement.
These were used subsequently in studies of the regulatory
mechanisms controlling gene transcription and protein
localization at genome-level [27,28].
Despite the availability of a more recent version of the
MultiSite Gateway cloning kit (MultiSite Gateway Pro)
Buj et al. BMC Molecular Biology 2013, 14:18 Page 10 of 16
http://www.biomedcentral.com/1471-2199/14/18that allows using any single-fragment destination vector in
two-, three-, or four-fragment recombination reactions
without further modification [29], we chose the earlier
version of the kit because this would allow the use of entry
vectors containing the attL1/attL2-flanked ORF of
interest as obtained from public sources, without
further subcloning. This is precluded in the Pro version of
the kit, since those att sites ought to lie on separate entry
vectors because of the kit’s configuration. Thus, with
a MultiSite Gateway Pro-based cloning platform, any
attL1/attL2 flanked-ORF of interest obtained from a
public repository would still have to be PCR-amplified
and subcloned into at least one pDONR vector appropri-
ate for the Pro version of the kit prior to the MultiSite
recombination reaction, blunting the advantage conferred
by the ready availability of the entry clone. In our
approach, engineering is instead restricted to the
destination vector of choice, which once adapted for
MultiSite Gateway recombination can be used to generate
multiple fusion proteins with the unmodified entry clones
from the library. Nevertheless, cloning platforms that use
the MultiSite Gateway Pro kit are perfectly possible
and one such has been developed [30], which allows
the versatile creation of minigenes to be used in
Drosophila transgenesis for the tissue-specific expression
of proteins, including fluorescent reporters. Platforms
reported in earlier publications, such as the Drosophila
Gateway vector collection devised by the Murphy lab at the
Carnegie Institution [31], and the Saccharomyces cerevisae
collection of Gateway destination vectors constructed at
the Lindquist lab [32] also allow directly producing fusion
proteins with both custom made-, or ORFeome-derived
entry clones, since their input consists of plasmids
containing ORFs flanked by attL1/attL2 sites, which are
used in single-fragment LR recombinations to generate the
expression vectors. In these platforms, though, variability
lies with the destination vectors, which contain functional
modules preinserted at 5′ or 3′ relative to the standard
Gateway cassette, which will be expressed in-frame
with the Gateway-shuttled ORF of interest. Since the
functional modules lie beyond the att sites, construction
of these platforms required complex cloning of Gateway
cassette-derivatives into a large number of expression
vectors in order to achieve the desired number of
module combinations.
Although toolkits for fusion protein construction
based on sequence-directed cloning methods provide
versatility and ease of use, the possible functional impact
of peptide “scars” linking the modules (resulting from
the translation of intervening residual cloning sites, see
above), needs to be taken into account [33]. In view of
this, other more economical, non-sequence-directed,
“seamless” recombinational cloning methods for joining
two or more DNA fragments without the operation ofextraneous sequences would represent an attractive
alternative [34,35]. Nevertheless, in the most widely used
seamless methods, DNA fragments to be assembled
ought to be amplified by PCR with primers that provide
some sequence overlap at their ends. The distribution of
these sequence overlaps among the fragments ensures
they are stitched together in the required order. In other
instances, “stitching” oligonucleotides can be used that
act as a bridge encompassing the ends of the unrelated
sequences to be joined [35]. In either case, the gener-
ation of a combinatorial cloning platform based on such
methods would involve prior knowledge of the fusions
that would be of interest in order to provide necessary
tools in advance. This would somewhat curtail the
implementation of high-throughput strategies based on
the use of ORFeome-derived clones, as it would require a
case-based design, which is not necessary when universal
external connectors (e.g. att sites) are used. Furthermore,
PCR-amplification of modules for constructing specific
fusions would require checking every resulting chimeric
cDNAs for the presence of unwanted mutations, while such
controls are only required at the time of subcloning if the
same modules are perpetuated as inserts of a plasmid in
the context of a Gateway-based platform. In the absence of
a perfect recombination-based solution, one ought to con-
sider what is best for a given application, whether lowering
the risk of encountering scar-derived functional effects, or
using high throughput applications. Nevertheless, this is no
obstacle to using both approaches in a complementary way
since, for instance, the assembly of composite modules
derived from the sequence of two or more proteins could
be achieved by using seamless recombinational cloning,
and the new modules could then be incorporated into
Gateway-based cloning platforms for their fusion to other
peptides. Interestingly, non-recombination-based cloning
platforms such as Golden Gate, Golden Braid, and MoClo
[33,36,37], which have shown great potential for scalability
in the construction of multipartite expression vectors, could
also be adapted for the seamless cloning of fusion proteins
with the possibility of using peptide-encoding modules
in high-throughput applications. Careful design of the
module-cloning strategy may allow the construction
of fusion proteins with a minimal contribution of scar
sequence between the modules [33,36]. The down-
sides are that these systems require that cloned DNA
fragments are free from the infrequent target sites for
the type IIS restriction enzymes they are based upon
(this may require the fragment’s sequence to be modi-
fied prior to cloning), and that the ORFs of interest
cannot be used straight from Gateway-based ORF
collections but would require PCR-amplification with
primers providing the appropriate restriction enzyme
sites. All in all, the above considerations should be a
guide for the future development of cloning strategies
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across different platforms.Conclusions
We describe the blueprint for a system that streamlines
the cloning of fusion proteins from Gateway-based,
ORF-containing entry clones. It is based on sets of plasmids
that encode customized functional modules to be fused to
an ORF of interest, plus an adaptor plasmid that allows
existing destination expression vectors to participate in
MultiSite cloning reactions leading to the cloning of fusion
proteins. Multiple fusions can thus be potentially assembled
from a single ORF in a combinatorial way, and expressed in
diverse cellular models. Expression vectors are easy to
construct and update, since cloning is based on Gateway
technology. We believe this approach will be widely useful
for the scientific community as it should extend the
range of possible studies based on fusion proteins
beyond those currently afforded by cloning vectors
with preinserted modules. Plasmids will be made available
through Addgene.Methods
Molecular biology
PCR reactions were carried out with AccuPrime Pfx
SuperMix (Life Technologies) as indicated by the
manufacturer. The pDONR plasmids and cloning vector
pDEST-R4-R3 were obtained as part of the MultiSite
Gateway cloning kit (Life Technologies catalog # 12537023).
Destination expression vector pEF5/FRT/V5-DEST was
obtained from Life Technologies (catalog # V6020-20). This
is a vector for cloning and expressing proteins in FLP-In™
isogenic cell lines. The expression of cloned proteins is
driven by the human elongation factor 1α promoter located
upstream of the Gateway cassette. The vector has an FRT
recombination site that mediates FLP recombinase-directed
integration of the vector into a unique homologous
FRT site in the genome of FLP-In™ cell lines, and the
hygromycin resistance gene acts as a selectable
marker for integration. Nevertheless, it behaves just
as any other expression vector in transient transfec-
tion experiments. BP- and LR-recombination reactions
were carried out with BP clonase II and LR Clonase
II Plus enzyme mixes, respectively (Life Technologies),
following the manufacturer’s instructions. Reactions
were stopped by addition of Proteinase K and incuba-
tion at 37°C for 10 min. All competent E. coli strains
were obtained from Life Technologies and used in
one-shot format for plasmid transformation. LB medium
was supplemented where indicated with selection an-
tibiotics at the following concentrations: ampicillin
(100 μg/mL), kanamycin (50 μg/mL), chloramphenicol
(50 μg/mL).Site-directed mutagenesis of the chloramphenicol-acetyl
transferase (CAT) gene in the Gateway cassettes
Inactivation of the type I CAT gene in the Gateway
selection cassette of pDONR221 and pEF5/FRT/V5-
DEST was achieved by site-directed mutagenesis. The
oligonucleotides 5′-CCCCCGTTTTCACCTAAGGCA
AATATTATAC-3′ (forward) and 5′-GTATAATATTT
GCCTTAGGTGAAAACGGGGG-3′ (reverse) were used
to introduce a nonsense mutation, replacing methionine
173 with a stop codon (underlined). This was designed to
cause the premature interruption of the 219-residue type I
CAT protein, resulting in the loss of the c-terminal
α-Helix 5 [38]. This region allows the formation of
the trimeric complex of identical subunits that constitutes
the functional enzyme, having additional positive effects on
the protein’s solubility [39]. The mutation was expected to
disrupt these properties and have profound deleterious
effects on the enzyme’s activity. The mutagenesis oligonu-
cleotides were designed so that an NcoI site would be
destroyed as a consequence of the mutation, which could
then be used for diagnostic purposes. The oligonucleotides
were used in combination with the QuikChange Lightning
site-directed mutagenesis kit (Agilent), with the exception
that transformation of the mutagenesis reactions was done
into ccdB Survival™ 2 T1R competent cells to avoid the
lethality of the ccdB gene in the Gateway selection cassette.
After transformation, the cultures were spread on LB/agar
dishes containing either ampicillin (pEF5/FRT/V5-DEST)
or kanamycin (pDONR221) to allow the growth of clones
containing the putatively mutant plasmids, since resistance
to these antibiotics would be unaffected. 10–20 Colonies
were picked and sequentially streaked first onto LB/agar
Petri dishes supplemented with ampicillin or kanamycin,
and secondly onto dishes additionally supplemented with
chloramphenicol, in order to identify colonies that were
sensitive to this antibiotic as a result of the mutation
in the CAT gene. Colonies that failed to grow in the
ampicillin/chloramphenicol (pEF5/FRT/V5-DEST) or
kanamycin/chloramphenicol (pDONR221) dishes were
identified, and their counterpart streak on the dish with a
single antibiotic was used to rescue the clone and prepare
plasmid. Since chloramphenicol sensitivity (CamS) could
also result from spontaneous mutation of the CAT
gene, the presence of the desired mutation was con-
firmed by digestion of the plasmids with NcoI and by
sequencing. The resulting chloramphenicol-sensitive,
mutant plasmids pDONR221_CamS and pEF5/FRT/V5-
DEST_CamS were subsequently used in recombination
reactions for the incorporation of the attR4-attR3
Gateway cassette.
Construction of pDONR221-R4-R3
The standard Gateway cassette in pDONR221 was replaced
by the attR4-attR3 MultiSite Gateway cassette, resulting in
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methodology described by Magnani et al. [13], with modifi-
cations. Firstly, we PCR-amplified the attR4-attR3-flanked
MultiSite Gateway cassette from vector pDEST-R4-R3 [13]
in two sequential PCR reactions, by using oligonucleotide
primers that added external attB1 and attB2 sites in
juxtaposition to the existing attR4 and attR3 sites,
respectively. The first PCR (10 cycles) was performed
with the oligonucleotide primer pair: 5′-AAAGCAG
GCTCAACTTTGTATAGAAAAGTTG-3 (attR4fw) and
5′-AAAGCTGGGTCAACTATGTATAATAAAGTTG-
3′ (attR3rv), while the second PCR reaction (32 cycles) was
carried out with the external primer pair: 5′-GGGGAC
AAGTTTGTACAAAAAAGCAGGCTCA-3′ (attB1-R4fw)
and 5′-GGGGACCACTTTGTACAAGAAAGCTGGGT
CA-3′ (attB2-R3rv), by using a 1:10 dilution of the first
PCR reaction in fresh Accuprime Pfx supermix as the
source of template. The final PCR product, which
contained an intact CAT gene, was used with plasmid
pDONR221-CamS in a BP recombination reaction for
1h at 25 °C. After transformation of the reaction into
ccdB Survival™ 2 T1R competent cells, the culture was
plated onto an LB/agar dish containing kanamycin and
chloramphenicol to select for colonies harbouring plasmids
that had successfully recombined with the PCR product
and were able to grow in the presence of chloramphenicol.
Colonies were picked for preparation of plasmid and
further analysis. The presence of the attR4 and attR3 sites
was confirmed by sequencing of the vector. The integrity
of the ccdB gene in pDONR221-R4-R3 was tested by
transformation of the vector into Top10 competent
cells, which are sensitive to the ccdB gene and failed
to grow in the presence of the vector.
Construction of pEF5/FRT/V5-DEST-R4-R3
Adaptation of pEF5/FRT/V5-DEST for MultiSite Gateway
cloning was carried out as described by Magnani et al.
[13], with modifications. Briefly, an LR recombination
reaction was carried out at 25°C for 16h between
plasmids pEF5/FRT/V5-DEST_CamS (see above) and
pDONR221-R4-R3. Importantly, the attR4/attR3 sites
in pDONR221-R4-R3 cannot recombine with the jux-
taposed attL1/attL2 sites [13]. After transformation
of the reaction into ccdB Survival™ 2 T1R competent
cells, the cultures were plated onto LB/agar dishes
containing ampicillin and chloramphenicol to select for
colonies harbouring the recombined pEF5/FRT/V5-DEST
plasmid. In this way, the attR1/attR2-flanked standard
Gateway cassette in pEF5/FRT/V5-DEST was substituted
by the attR4/attR3-flanked MultiSite Gateway cassette,
obtaining pEF5/FRT/V5-DEST-R4-R3, which was ready
for a MultiSite LR recombination cloning reaction
with the three modules that would make up the fusion
protein of choice.Entry clones containing the ORFs of interest
The entry clones for p65 and PAR-2 were generated by BP
clonase-mediated recombination reactions (1 h, 25°C)
between vector pDONR221 and purified PCR-products
representing each of the full-length cDNAs. Nevertheless,
purification of PCR products prior to BP cloning is not
essential as the reactions also work well with non-purified
PCR products. To make those entry clones apt for
optional single-fragment recombination into a standard
destination vector, part of a Kozak sequence (GCCGCC)
was included in the forward primers, 5′to the ATG
initiation codon, in order to optimise translation of
the cDNA. Thus, when the same entry clone participated
as a central element in the cloning of a fusion protein, the
Kozak sequence translated into two alanine residues
preceding the initial methionine. The stop codon was
omitted from the cDNA-specific sequence of the reverse
primers so as to allow the construction of fusions with a
C-terminal module. The PCR products were generated by
using a two-step PCR method similar to that used to
amplify the attR4-attR3-flanked MultiSite Gateway
cassette. In the first PCR reaction, a set of primers
that contained part of the attB1 (forward primer) or attB2
(reverse primer) recombination sites followed by template-
specific sequence (Additional file 3: Table S1), was used
in combination with a template-containing plasmid, in
a 10-cycle PCR reaction. A second, 32-cycle PCR reaction
was set up by diluting 1/10 the first PCR reaction,
and supplementing it with a new set of primers
(Additional file 3: Table S1) that were complementary to
the partial attB1 (forward primer) or attB2 (reverse primer)
sequences incorporated into the PCR product by the first
set of primers, and that extended the recombination sites
to the full length recommended by Life Technologies
for BP clonase-mediated cloning. This two-step method
allowed the use of the second set of primers in multiple
cloning projects since the specificity with regard to the
cDNA relied on the sequence of the first set of primers,
resulting in potential savings in the costs of oligonucleo-
tide synthesis in the long term. It should be noted that this
is not a technical requirement since one-step PCR
reactions with primers providing full-length, flanking
attB sites are widely used for Gateway cloning of
PCR products. The cDNA fragment comprising positions
141 to 1793 of the human p65/RelA mRNA sequence
(accession number NM_021975.3), excluding the natural
stop codon, was amplified as described above from
plasmid pCDNA3.1-p65 [40], with the primers indicated
in Additional file 3: Table S1. The mouse thrombin
receptor PAR-2 cDNA was amplified from the
FANTOM Full Length cDNA clone number G8300117P07
(pFLCI-PAR2, The Institute of Physical and Chemical
Research (RIKEN) [41]), with primers (Additional file 3:
Table S1) that encompassed the sequence between
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number NM_007974). For the fusion protein that contained
the full-length mouse SIRT1 coding sequence, we
used an IMAGE ORFeome collaboration clone (100066295)
with the SIRT1 cDNA already flanked by attL1/attL2
sites in vector pENTR223-SfiI [42]. Cultures of bac-
teria transformed with this plasmid were grown with
LB medium containing 50 μg/ml spectinomycin. A mouse
SIRT1 cDNA with a deletion that affected a region near
the N-terminus of the protein (ΔN-t-SIRT1) was amplified
from plasmid pUSEamp SIRα2 (Millipore). This internal
deletion affected residues Leu7 to Ala123 but did not
disrupt the rest of the ORF, causing the loss of a region
encompassing the N-terminal nuclear location signal NLS1
[19]. The deletion was caused by off target annealing of the
forward primer in the first PCR reaction (Additional file 3:
Table S1), to a sequence lying 354 bp downstream of the
target sequence. The full attB1 and attB2 sites were com-
pleted in a second PCR by using the universal set of
primers, and the PCR product was cloned into pDONR221
through BP clonase-mediated recombination, as described
above. All PCR primers used were designed so that the
eventual attB1/attB2-flanked PCR products would be in
frame in the context of three-fragment recombinations for
the production of fusion proteins. The sequence of all
clones was verified by sequencing.
Construction of the modules’ collections
The collections of N-terminal and C-terminal modules
were constructed as clones containing DNA inserts in
vectors pDONR P4-P1R and pDONR P2R- P3, respect-
ively. The inserts (italics) were PCR-amplified from the fol-
lowing plasmid templates: mKate2, pmKate2-C (Evrogen);
EGFP, pLV-EGFP (kind gift from M. Perez-Pinzon, UM);
EYFP, pEYFP-mito (Clontech); ECFP and IRES_ECFP, pYIC
(Addgene plasmid 18673 [43]; V5-6xHis epitope tag
cassette, pEF6/V5-His (Life Technologies). Construction of
the clone containing the SV40 early polyadenylation signal
has previously been described [44]. All inserts were ampli-
fied in a two-step PCR reaction, similarly to the way
described in the section above, with the primers described
in Additional file 3: Table S1. In this case, the primers
attached flanking attB4/attB1R sites to the PCR products
to be cloned into pDONRP4-P1R, while those to be cloned
into pDONRP2R-P3 were furnished with attB2R/attB3
sites. When the functional modules were cloned into
pDONR-P4-P1R (N-terminal modules), the forward primer
in the first pair contained a Kozak sequence in order to
improve translation of the fusion protein. Furthermore, if
the template sequence contained a stop codon, this was
not included when designing the reverse primer of
the first pair so as to avoid interrupting translation
downstream of the module. Nevertheless, when the
module was to be located at the C-terminal end ofthe fusion (a pDONRP2R-P3-based clone), the stop
codon was allowed into the sequence of the reverse
primer of the first pair. Cloning of the PCR products into
their corresponding pDONR vector was carried out by
using BP clonase, as described above. The sequence of all
clones was verified by sequencing.
Cloning of fusion proteins into pEF5FRTV5DEST-R4-R3
Chimeric ORFs for the expression of fusion proteins
were assembled by performing MultiSite LR recombin-
ation reactions between the three selected entry clones
and the adapted pEF5FRTV5DEST-R4-R3 destination
expression vector. Ten femtomoles of Maxiprep-quality
DNA from each entry vector were mixed with 20
femtomoles of the destination expression vector and 2 μl
of LR Clonase II plus enzyme mix (Life technologies) in
a final volume of 10 μl and incubated for 16 h at 25°C,
following instructions from the manufacturer. A 2-μl
aliquot of the reaction was transformed into either
Top10 or stbl3 E. coli, and the reaction was plated on
LB-agar medium supplemented with ampicillin to select
transformed bacteria. Colonies potentially containing
recombined pEF5FRTV5DEST expression vectors with
the chimeric ORF were picked with sterile pipette tips
and streaked onto Petri dishes containing LB-agar
medium plus ampicillin in order to amplify them. These
cultures were subsequently streaked on Petri dishes
containing LB-agar medium supplemented with ampicil-
lin and chloramphenicol in order to check for the pres-
ence of colonies containing non-recombined destination
expression vector that may have spontaneously mutated
the ccdB gene in the Gateway cassette. The same col-
onies were also tested for growth on plates with LB-agar
medium containing the antibiotic to which the entry
clones that had been used in the LR reaction conferred
resistance to (kanamycin, spectinomycin), since we
observed an occasional phenomenon of cotransformation
of the destination expression vector with the entry clones.
This was observed even though both the pDONR series of
plasmids and pEF5FRTV5DEST contain the same origin
of replication and thus belong to the same incompatibility
group. This is a phenomenon that has been thoroughly
described elsewhere [45,46], and needs to be taken into
account as it could be a confounding factor in plasmid
preparations that are destined to be transfected. Future
refinements of this method will have to be devised in
order to avoid such cotransformation events in high-
throughput applications. Only the colonies that grew
exclusively on LB plus ampicillin were used for further
tests. In our hands, screening of about 20–25 colonies per
transformation was sufficient to find colonies harbouring
the expression vector in the absence of “piggybacking”
entry clones. The integrity of the chimeric ORFs in
the recombined expression vectors was checked both
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the expected colony yield, colony counting after transform-
ation of half the reaction volume in a dedicated series of
reactions resulted in 258 ± 54 (mean ± SD, n = 5) colonies
per Petri dish. This number is lower than the range
suggested by Life technologies in the Multisite Gateway
cloning kit user’s manual (1000–5000 colonies, when
the whole transformation is plated), which could be
caused by procedural differences introduced as a result of
our toolkit’s design. In any case, colony numbers expected
from Multisite Gateway reactions are still below
those produced in single-fragment LR recombinations
(see Life Technologies’ Gateway user manuals) because of
the participation of more DNA fragments, which should
be taken into account when planning Multisite Gateway
LR recombination reactions.
Expression of fusion proteins
Expression vectors encoding chimeric ORFs were
introduced into HeLa cells or Raw264.7 murine
monocytes, in transient transfection experiments. Both
cell lines were kindly provided by Dr Andy Clark
(University of Birmingham, UK). In the case of HeLa
cells, 1.5×104 cells per well were seeded on top of
glass coverslips in 24-well plates. Cells were transfected
with expression vectors for mKate2 fused to wt SIRT1 or
ΔN-t-SIRT1 (both with N-terminal mKate2), or PAR-2
(with mKate2 fused to the C-terminus of PAR2), as well as
for PAR-2 fused to EGFP (also in a C-terminal fusion to
PAR-2). One μg of plasmid DNA was transfected with 3
μl of Lipofectamine reagent (Life Technologies), following
the manufacturer’s instructions. Forty-eight hours after
transfection, cells transfected with the PAR-2 fluorescent
fusions were either left untreated (control) or treated for 1
h with the PAR-2 specific agonist AC55541 (Tocris) at a 5
μM final concentration. At the end of the treatments, cells
were fixed with 4% paraformaldehyde, rinsed in cold
methanol followed by a brief wash in H2O and
mounted in Fluoromount G (Southern Biotech). Cells
were observed under a Nikon Eclipse E1000 fluorescence
microscope. For the Raw264.7 cell line, 105 cells per well
were seeded on 24-well plates. Cells were transfected with
1 μg of maxiprep-quality plasmid DNA and 3.2 μl of
jetPEI-Macrophage reagent (Polyplus transfection) per
well, according to the manufacturer’s instructions. The
transfected expression vectors encoded for fusions of p65
with the red fluorescent protein mKate2. Forty-eight
hours after transfection, cells were either left in control
conditions or treated with LPS, and were observed live
under an Olympus IX70 fluorescence inverted- micro-
scope. For the time-lapse experiment, Raw 264.7 cells
seeded on a 25 mm Ø glass coverslip in a well of a
six-well plate were transfected with the expression
vector for the PAR2: mKate2 fusion protein and mountedin a chamber equipped with an incubation system with
temperature control, in a Leica TCS-SL confocal inverted
microscope (63X objective lens). A transfected cell was
imaged live, with micrographs taken at 20 sec intervals,
both under control conditions or after treating with 5 μM
AC55541.
Additional files
Additional file 1: Figure S1. Single fragment and MultiSite Gateway
recombinational cloning. In the Gateway system, DNA fragments (such as a
cDNA) can be PCR-amplified with primers that attach flanking attB1/attB2
sites (B1, B2), and cloned into a compatible vector by carrying out a BP
recombination (BP rec.). This generates a so-called Entry clone where the
DNA fragment is flanked by attL1/attL2 sites (L1, L2), and that can be
subsequently used to shuttle the DNA fragment into destination vectors that
provide specific functions. In standard single-fragment Gateway cloning, an
attL1/attL2-flanked cDNA in the example is transferred to a destination vector
that contains compatible attR1/attR2 sites through an LR-recombination
reaction (LR rec.). On the other hand, in the MultiSite Gateway cloning
system, three different entry clones with DNA fragments flanked by
sequence variants of the attL and attR sites (L3, L4, R3, R4) participate in a
multi-fragment LR-recombination reaction with the promoter-less destination
vector pDEST-R4-R3. This vector contains a Gateway cassette that is flanked
by attR4/attR3 sites, which conditions the order of recombination of the
three fragments in the resulting destination vector owing to the nature of
their respective flanking att sites, as indicated.
Additional file 2: Figure S2. Mutation of the CAT gene in the Gateway
cassette of pEF5FRT-DEST abolishes resistance to chloramphenicol.
Cultures of ccdB-resistant E. coli transformed with pEF5FRT-DEST
encoding a wild type (a,c), or a mutant version of the CAT gene (b, d),
were streaked on LB-agar dishes containing ampicillin (a,b) or ampicillin
plus chloramphenicol (c,d). While bacteria transformed with either of the
plasmids were able to grow in the presence of ampicillin, further
supplementation of the medium with chloramphenicol specifically
prevented the growth of bacteria transformed with the plasmid
containing the mutation of the CAT gene (d).
Additional file 3: Table S1. Sequence of the oligonucleotides used for
PCR amplification. Two-step PCRs were set up with the primers indicated
on the table (fw: forward, rv: reverse) in order to attach the appropriate attB
sites to the functional modules to be cloned by BP clonase-mediated
recombination. The module-specific primers were used in the first PCR and
contain part of the att sequence. The universal external primers were used
in the second PCR to complete the att sites. In the module-specific primers,
sequence in capitals corresponds to the oligonucleotide segment that
anneals to the template, while the sequence in bold type is annealed by
the universal external primer that will complete the corresponding att site.
The same forward and reverse primers were used for the PCR amplification
of EGFP, ECFP and EYFP, since the mutations dictating the fluorescence
wavelength lie beyond the sequence annealed by the primers. The
N-terminal V5-6xHis module was PCR-amplified with a three-step PCR.
The first forward module-specific primer (a) attached a Kozak sequence
and an initiation methionine codon to the cassette containing the epitope
tags, but no att-related sequence (∅), while the second PCR was carried
out with a second forward primer (b) that provided the seed for the attB4
site. This site was completed in the last PCR, which was carried out with
the corresponding external universal primers. Only one reverse
module-specific primer was used in the first and second PCRs for
this module.
Additional file 4: Figure S3. Versatility of the cloning toolkit. A.
Simultaneous construction of vectors expressing versions of the same
fusion protein coupled to different fluorescent modules, offering a choice
of optical properties in experiments where individual or multiple fusion
proteins are expressed. B. A library of mutations can be generated in the
vector encoding the ORF of interest so recombination of the library with
intact functional modules would allow the generation of a homogeneous
range of expression vector mutation libraries to be screened on different
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functional modules flanking the ORF of interest are in either of the two
possible orders, to evaluate putative effects on protein function.
Additional file 5: Movie 1. Complete time-lapse sequence recorded on
the PAR2:mKate2-expressing cell shown in Figure 4C. The sequence
spans an almost one-hour period, with the AC55541 agonist added right
at the start.
Additional file 6: Movie 2. Time-lapse recording of the same cell as in
Additional file 5: Movie 1, recorded under control conditions for 11 min
before adding the AC55541 agonist.
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